{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T14:14:32Z","timestamp":1789568072826,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.bbmt.2015.03.012","type":"journal-article","created":{"date-parts":[[2015,3,29]],"date-time":"2015-03-29T14:32:39Z","timestamp":1427639559000},"page":"1230-1236","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?"],"prefix":"10.1016","volume":"21","author":[{"given":"Aleksandar","family":"Radujkovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesare","family":"Guglielmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Bergantini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Iacobelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"van Biezen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragana","family":"Milojkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alois","family":"Gratwohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonius V.M.B.","family":"Schattenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo F.","family":"Verdonck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietger W.","family":"Niederwieser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo","family":"de Witte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolaus","family":"Kr\u00f6ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Olavarria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2015.03.012_bib1","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.beha.2009.05.002","article-title":"Current role of stem cell transplantation in chronic myeloid leukaemia","volume":"22","author":"Gratwohl","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.bbmt.2015.03.012_bib2","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.03.012_bib3","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1586\/ehm.10.32","article-title":"Relapse after allogeneic stem cell transplantation","volume":"3","author":"Barrett","year":"2010","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.bbmt.2015.03.012_bib4","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.beha.2006.10.002","article-title":"Disease relapse after haematopoietic stem cell transplantation: risk factors and treatment","volume":"20","author":"Dazzi","year":"2007","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.bbmt.2015.03.012_bib5","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ctrv.2010.03.004","article-title":"Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited","volume":"36","author":"Deol","year":"2010","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.bbmt.2015.03.012_bib6","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/JCO.1997.15.2.433","article-title":"Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation","volume":"15","author":"Collins","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2015.03.012_bib7","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1053\/bbmt.1999.v5.pm10465105","article-title":"Long-term follow-up of patients who achieved complete remission after donor leukocyte infusions","volume":"5","author":"Porter","year":"1999","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.03.012_bib8","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1182\/blood.V96.8.2712","article-title":"Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia","volume":"96","author":"Dazzi","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.03.012_bib9","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1182\/blood.V83.11.3377.3377","article-title":"Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse","volume":"83","author":"van Rhee","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.03.012_bib10","first-page":"389","article-title":"Evaluation of remission state in chronic myeloid leukemia patients after bone marrow transplantation using cytogenetic and molecular genetic approaches","volume":"4","author":"Arnold","year":"1989","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.03.012_bib11","first-page":"3328","article-title":"Risk assessment in patients with Ph+ chronic myelogenous leukemia at first relapse after allogeneic stem cell transplant: an EBMT retrospective analysis. The Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation","volume":"95","author":"Guglielmi","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.03.012_bib12","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1182\/blood.V99.10.3861","article-title":"Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation","volume":"99","author":"Olavarria","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.03.012_bib13","doi-asserted-by":"crossref","first-page":"7583","DOI":"10.1200\/JCO.2005.01.3110","article-title":"Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study","volume":"23","author":"Hess","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2015.03.012_bib14","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1182\/asheducation-2006.1.226","article-title":"Managing the patient with chronic myeloid leukemia through and after allogeneic stem cell transplantation","author":"Apperley","year":"2006","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.bbmt.2015.03.012_bib15","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/blood.V86.5.2041.bloodjournal8652041","article-title":"Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients","volume":"86","author":"Kolb","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.03.012_bib16","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood.V100.2.397","article-title":"Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose","volume":"100","author":"Guglielmi","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.03.012_bib17","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/bmt.2009.177","article-title":"Outcome of patients developing GVHD after DLI given to treat CML relapse: a study by the Chronic Leukemia Working Party of the EBMT","volume":"45","author":"Chalandon","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.03.012_bib18","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1182\/blood-2003-02-0342","article-title":"Graft-versus-leukemia reactions in allogeneic chimeras","volume":"103","author":"Kolb","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.03.012_bib19","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(84)92179-2","article-title":"Allogeneic bone-marrow transplantation for chronic myelogenous leukaemia","volume":"1","author":"Speck","year":"1984","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2015.03.012_bib20","series-title":"Using and understanding Medical Statistics","author":"Matthews","year":"1996"},{"key":"10.1016\/j.bbmt.2015.03.012_bib21","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1182\/blood.V86.4.1261.bloodjournal8641261","article-title":"Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease","volume":"86","author":"Mackinnon","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.03.012_bib22","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1182\/blood.V95.1.67","article-title":"Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia","volume":"95","author":"Dazzi","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.03.012_bib23","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/sj.bmt.1703883","article-title":"Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusions","volume":"31","author":"Raiola","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.03.012_bib24","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.bbmt.2013.03.001","article-title":"Donor lymphocyte infusion for relapsed hematological malignancies after allogeneic hematopoietic cell transplantation: prognostic relevance of the initial CD3+ T cell dose","volume":"19","author":"Bar","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.03.012_bib25","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/sj.leu.2404641","article-title":"Response to donor lymphocyte infusions for chronic myeloid leukemia is dose-dependent: the importance of escalating the cell dose to maximize therapeutic efficacy","volume":"21","author":"Simula","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2015.03.012_bib26","first-page":"663","article-title":"A\u00a0comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation","volume":"91","author":"Weisser","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2015.03.012_bib27","doi-asserted-by":"crossref","first-page":"e65981","DOI":"10.1371\/journal.pone.0065981","article-title":"Is Imatinib Maintenance Required for Patients with Relapse Chronic Myeloid Leukemia Post-Transplantation Obtaining CMR? A Pilot Retrospective Investigation","volume":"8","author":"Jin","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bbmt.2015.03.012_bib28","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/sj.bmt.1705167","article-title":"Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation","volume":"36","author":"Savani","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.03.012_bib29","doi-asserted-by":"crossref","first-page":"5065","DOI":"10.1158\/1078-0432.CCR-03-0580","article-title":"Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease","volume":"10","author":"DeAngelo","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbmt.2015.03.012_bib30","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1038\/sj.leu.2403068","article-title":"Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia","volume":"17","author":"Olavarria","year":"2003","journal-title":"Leukemia"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879115001846?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879115001846?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:51:10Z","timestamp":1761058270000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879115001846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["S1083879115001846"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2015.03.012","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2015.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}